SMN2 and proximal spinal muscular atrophy: In conclusion, on the basis of our observations, agrin biological NT-1654 represents a good therapeutic candidate for SMA, counteracting agrin deficiency and SMN-induced defects: it should be exploited in combination with the emerging promising therapies aimed at increasing SMN expression.